Barrett esophagus

Current Opinion in Gastroenterology

Volumn 20, Issue 4, 2004, Pages 375-380

  Bonino, John A ^a   Sharma, Prateek ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Barrett esophagus; Dysplasia; Esophageal adenocarcinoma; Esophageal dysplasia; Intestinal metaplasia

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CANCER EPIDEMIOLOGY; CANCER INHIBITION; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER THERAPY; CARCINOGENESIS; COST EFFECTIVENESS ANALYSIS; DYSPLASIA; ESOPHAGUS CARCINOMA; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; INTESTINE METAPLASIA; PROCESS DEVELOPMENT; REVIEW; RISK ASSESSMENT; RISK REDUCTION; TREATMENT INDICATION;

EID: 3042647168     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200407000-00013     Document Type: Review

References (25)

1. Daly JM, Karnell LH, Menck HR: National cancer data base report on esophageal carcinoma. Cancer 1996, 78:1820-1828.
2. Rex DK, Cummings OW, Shaw M, et al.: Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003, 125:1670-1677. An investigation of the prevalence of Barrett esophagus between individuals with heartburn (8.3%) and those without heartburn (2.5%).
3. Fletcher J, Gillen D, Wirz A, et al.: Barrett's esophagus evokes a quantitatively and qualitatively altered response to both acid and hypertonic solutions. Am J Gastroenterol 2003, 98:1480-1486. This study suggests a lower intensity of symptoms in patients with Barrett esophagus. This finding may be secondary to the better ability of columnar mucosa to withstand low pH exposures rather than the native squamous epithelium.
4. Mokhashi MS, Wildi SM, Glenn TF, et al.: A prospective, blinded study of diagnostic esophagoscopy with a superthin, stand-alone, battery-powered esophagoscope. Am J Gastroenterol 2003, 98:2383-2388. A study of alternative ways to screen for Barrett esophagus instead of standard endoscopy, which requires sedation. Cost effectiveness and reduction of mortality will be important in any large-scale screening or surveillance protocol.
5. Nietert PJ, Siverstein MD, Mokhashi MS, et al.: Cost-effectiveness of screening a population with chronic gastroesophageal reflux. Gastrointest Endosc 2003, 57:311-317.
6. Yagi K, Nakamura A, Sekine A: Accuracy of magnifying endoscopy with methylene blue in the diagnosis of specialized intestinal metaplasia and short-segment Barrett's esophagus in Japanese patients without Helicobacter pylori infection. Gastrointest Endosc 2003, 58:189-195.
7. Olliver JR, Wild CP, Sahay P, et al.: Chromoendoscopy with methylene blue and associated DNA damage in Barrett's oesophagus. Lancet 2003, 362:373-374.
8. Conio M, Blanci S, Lapertosa G, et al.: Long term endoscopic surveillance of patients with Barrett's esophagus: incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003, 98:1931-1939. This cohort study monitored individuals with Barrett esophagus for a mean duration of 5.5 years and showed a cancer incidence in 1 in 220 patient years of follow up.
9. Anderson L, Murray L, Murphy S, et al.: Mortality in Barrett's oesophagus: results from a population based study. Gut 2003, 52:1081-1084.
10. Murray L, Watson P, Johnston B, et al.: Risk of adenocarcinoma In Barrett's oesophagus: population based study. Br Med J 2003, 327:534-535.
11. Gopal DV, Lieberman DA, Margaret N, et al.: Risk factors for dysplasia in patients with Barrett's esophagus: results from a multicenter consortium. Dig Dis Sci 2003, 48:1537-1541. Better identification of risk factors for esophageal adenocarcinoma development is the cornerstone of screening and surveillance protocols that would be high yield and cost effective.
12. Buttar NS, Wang KK, Sebo TJ, et al.: Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001, 120:1630-1639.
13. Dar MS, Goldblum JR, Rice TW, et al.: Can extent of high-grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy? Gut 2003, 52:486-489. Forty-two patients with a history of HGD who had undergone esophagectomy were examined for the extent of HGD. Of the 24 individuals found to have adenocarcinoma, the extent of HGD did not necessarily correlate to the presence of adenocarcinoma.
14. Indonami JM, Sampliner R, Lagergren J, et al.: Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003, 138:176-188. The benefits and cost effectiveness of screening and surveillance in patients with Barrett esophagus is unknown. This decision analysis found that screening patients older than 50 years of age with chronic GERD could be cost effective, as was surveillance of those with dysplasia.
15. Sharma P, Weston AP, Topalovski M, et al.: Magnification chromoendoscopy for the detection of intestinal metaplasia and dysplasia in Barrett's esophagus. Gut 2003, 52:24-27.
16. Endo T, Awakawa T, Takahashi H, et al.: Classification of Barrett's epithelium by magnifying endoscopy. Gastrointest Endosc 2002, 55:641-647.
17. Lord RVN, Park JM, Wickramasinghe K, et al.: Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett's esophagus. J Thorac Cardiovasc Surg 2003, 125:246-253.
18. Doak SH, Jenkins GJS, Parry EM, et al.: Chromosome hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus. Gut 2003, 52:623-628. In this study, chromosome four hyperploidy was found to be the most prominent chromosomal abnormality in 89% of patients with Barrett esophagus. The implication for the future may be the identification of genetic abnormalities in nonneoplastic biopsy specimens to risk-stratify individuals who would benefit from surveillance.
19. Vaezi ME, Richter JE: Role of acid and duodeno-gastro-esophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996, 111:1192-1199.
20. Smythe A, Bird NC, Troy GP, et al.: Does the addition of a prokinetic to proton pump inhibitor therapy help reduce duodenogastro-oesophageal reflux in patients with Barrett's oesophagus? Eur J Gastroenterol Hepatol 2003, 15:305-312.
21. Parilla P, Martines de Haro LF, Ortiz A, et al.: Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003, 237:291-298. This investigation evaluated the conditions of 101 patients with Barrett esophagus who underwent medical acid suppression therapy or a surgical antireflux procedure. The median follow-up time was 5 years in the medical group and 6 years in the surgical treatment group. There was no statistically significant difference in progression to dysplasia or adenocarcinoma between the two groups.
22. Gurski RR, Peters JH, Hagen JA, et al.: Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg 2003, 196:706-713.
23. Corey KE, Schmitz SM, Shaheen NJ: Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol 2003, 98:2390-2394. This meta-analysis reviewed the published literature from 1966 to 2001 involving the surgical and medical treatment of patients with Barrett esophagus. No significant difference was found in the incidence of adenocarcinoma between the medically and surgically treated groups.
24. Overholt BF, Panjehpour M, Halberg DL: Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003, 58:183-188. This study investigates photodynamic therapy and acid suppression in patients with dysplasia and early adenocarcinoma in Barrett esophagus. This study shows a high rate of elimination of neoplasia following endoscopic ablation.
25. Corley DA, Kerlikowske K, Verma R, et al.: Protective association of aspirin/NSAID and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003, 124:47-56. This study gives a meta-analysis showing a reduction in esophageal adenocarcinoma risk in individuals taking asprin or nonsteroidal agents.